|
|
|
| Market Competition Pattern of Global PD-1/PD-L1 Monoclonal Antibody |
Kai-yun MAO,Yue-lei FAN,Heng-zhe WANG,Da-ming CHEN( ) |
| Shanghai Information Center for Life Sciences, Chinese Academy of Sciences,Shanghai 200031,China |
|
|
|
Abstract Objective:To analyze the development status and trend of PD-1/PD-L1 monoclonal antibody in the sense of product manufacturing.Methods:Based on the Cortellis database of Clarivate analytics, the searching results with utilizing quantitative analysis and comparative analysis methods were analyzed.Results:Currently, five PD-1/PD-L1 monoclonal antibodies have been launched into markets, another three PD-1/PD-L1 monoclonal antibodies are at registration phase and four at phase III clinical trial. In addition, business deals related to PD-1/PD-L1 monoclonal antibody are increasing in recent years, including more than 10 deals so far, ranging from drug development, commercial license, and patent assets sales to drug R&D cooperation in early phase. As for China, several PD-1/PD-L1 monoclonal antibodies are at clinical stage, and a bright prospect can be expected for Chinese oligonucleotide therapeutic product markets.Conclusion:Although PD-1/PD-L1 monoclonal antibody market still at its preliminary stage, however, with the continuous development and improvement of future technology, it is believed that more PD-1/PD-L1 monoclonal antibody will be launched in the future, providing a new opportunity for the treatment of cancer and other diseases.
|
|
Received: 03 May 2018
Published: 06 December 2018
|
|
|
|
Corresponding Authors:
Da-ming CHEN
E-mail: chendaming@sibs.ac.cn
|
|
|
| [1] |
Ishida Y, Agata Y, Shibahara K . Induced expression of PD-1,a novel member of the immunoglobulin gene superfamily,upon programmed cell death. Embo Journal, 1992,11(11):3887-3895.
doi: 10.1089/dna.1992.11.707
pmid: 1396582
|
|
|
| [2] |
Dong H D, Zhu G F, Tamada K , et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nature Medicine, 1999,5(12):1365-1369.
doi: 10.1038/70932
pmid: 10581077
|
|
|
| [3] |
Freeman G J, Long A J, Iwai Y . Engagement of the PD-1 immunoinhibitory receptor by a novel B7-family member leads to negative regulation of lymphocyte activation. Blood, 2000,96(11):810A-811A.
doi: 10.1084/jem.192.7.1027
pmid: 11015443
|
|
|
| [4] |
Robert C, Schachter J, Long G V , et al. Pembrolizumab versus Ipilimumab in advanced melanoma. New England Journal Of Medicine, 2015,372(26):2521-2532.
doi: 10.1056/NEJMoa1503093
|
|
|
| [5] |
Martin R, Delvys R A, Andrew G R , et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. New England Journal of Medicine, 2016,375(19):1823-1833.
doi: 10.1056/NEJMoa1606774
|
|
|
| [6] |
Weber J, Mandala M, Del V M , et al. Adjuvant nivolumab versus Ipilimumab in resected stage III or IV melanoma. New England Journal of Medicine, 2017,377(19):1824-1835.
doi: 10.1056/NEJMoa1709030
pmid: 28891423
|
|
|
| [7] |
Carbone D P, Reck M, Paz-Ares L , et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. New England Journal of Medicine, 2017,376(25):2415-2426.
doi: 10.1056/NEJMoa1613493
|
|
|
| [8] |
Massard C, Gordon M S, Sharma S , et al. Safety and efficacy of Durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. Journal of Clinical Oncology, 2016,34(26):3119-3125.
doi: 10.1200/JCO.2016.67.9761
|
|
|
| [9] |
Garassino M C, Cho B C, Kim J H , et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC):an open-label, single-arm, phase 2 study. Lancet Oncology, 2018,19(4):521-536.
doi: 10.1016/S1470-2045(18)30144-X
pmid: 29545095
|
|
|
| [10] |
Rittmeyer A, Barlesi F, Waterkamp D , et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet, 2017,3899(10066):255-265.
|
|
|
| [11] |
Kaufman H L, Russell J, Hamid O , et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncology, 2016,17(10):1374-1385.
doi: 10.1016/S1470-2045(16)30364-3
|
|
|
| [12] |
Apolo A B, Infante J R, Balmanoukian A , et al. Avelumab, an Anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study. Journal of Clinical Oncology, 2017,35(19):2117-2124.
doi: 10.1200/JCO.2016.71.6795
|
|
|
| [13] |
Yang S, Yang J L, Han Y , et al. A phase 1 trial of JS001, a monoclonal antibody targeting programmed death-1 (PD-1) in patients with advanced or recurrent malignancies. Journal of Clinical Oncology, 2017,35(15):e14581-e14581.
doi: 10.1200/JCO.2017.35.15_suppl.e14581
|
|
|
| [14] |
Wang F, Qin S K, Fang W J , et al. Clinicopathological report of cutaneous capillary endothelial proliferation related with anti-PD-1 monoclonal antibody SHR-1210 in the treatment of primary hepatic carcinoma. Chinese Clinical Oncology, 2017,22(12):1066-1072.
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
